Matrixyl 3000 vs Synthe'6: OEM Cost and Formula Guide

Confirm what each trade name means in the quotation

Matrixyl 3000 is associated with a system containing Palmitoyl Tripeptide-1 and Palmitoyl Tetrapeptide-7. Matrixyl Synthe'6 is associated with Palmitoyl Tripeptide-38. Trade names belong to specific supplied grades and should not be used casually for generic look-alikes. Request manufacturer code, full INCI, carrier, preservative, active basis and trademark-use conditions. If an OEM substitutes a generic grade, the formula, cost and evidence file must be recalculated.

Normalize the quote to cost per active dose

Create one spreadsheet line for delivered stock-solution cost, one for active peptide content and one for proposed formula dose. Add freight, duties, loss, minimum purchase and expiry risk. A low-active stock at a high recommended use level can add substantial water and glycol while consuming more warehouse cash. Cost per 30-milliliter finished unit is the number the brand needs; price per kilogram of raw material is only an input.

Carrier load changes the base formula

Commercial lipophilic peptide blends often rely on water, glycerin, glycols, solubilizers or preservatives. At the recommended use level, those components affect tack, viscosity and preservation. Two systems cannot be swapped one-for-one while keeping the base untouched. Rebalance humectants and check polymer electrolyte tolerance. When a pilot becomes stringy or loses body, review the added carrier before changing the peptide dose.

Choose by claim architecture, not ingredient count

Matrixyl 3000 offers a two-peptide story; Synthe'6 centers on Palmitoyl Tripeptide-38. Neither format is automatically superior. Decide whether the product needs a recognizable multi-peptide narrative, a single focused hero or a blend with other actives. More INCI names can help merchandising but make claim attribution and stability harder. The strongest commercial brief usually has one primary claim, a defined consumer group and a test that can actually measure it.

Evidence does not transfer across every supplier grade

Published work on palmitoylated peptides and supplier studies can support technical rationale, yet vehicle, concentration and study design matter. Ask whether the evidence covers the exact commercial material, a prototype or a finished branded formula. Do not convert fibroblast data into a guaranteed wrinkle result. If a quantified claim appears on pack, substantiate the final serum at its marketed directions and shelf-life condition.

Model the OEM project beyond formula cost

Include sample rounds, stability, challenge testing, compatibility, safety assessment, artwork, labels, cartons, filling loss and retained samples. A premium peptide may add less to the unit cost than a custom bottle or low-volume decoration. Conversely, an apparently modest active cost can become material at high use level. Ask the OEM to separate one-time development charges from recurring unit costs so scale-up economics remain visible.

Run parallel pilots under the same conditions

Build matched prototypes with comparable sensory targets, package and supporting ingredients. Record order of addition, temperature, pH, viscosity and appearance. Test them side by side, not months apart under different lab conditions. Include an active-free control if the development budget allows. This makes it easier to see whether a stability change comes from the peptide system, the base or ordinary batch variation.

A procurement decision rule

Choose the grade whose identity, active basis, evidence rights, supply continuity and finished-unit cost fit the project. Reject a quotation that hides composition behind a marketing name or cannot provide sample-to-bulk equivalence. Lock the product code and change-notification clause in the purchase specification. The final formula should survive its intended package and claim review before either trade name appears in sales material.

A sample cost comparison without false precision

For each candidate, calculate cost at low, target and high supplier-recommended use levels. Put active stock, base adjustment, testing allocation and expiry loss in separate columns. Then model 1,000, 5,000 and 20,000 saleable units. The exercise often shows that peptide cost dominates at small pilot scale because the minimum raw-material pack is underused, while packaging dominates once volume increases. Add a scenario for combining both systems and another for a generic substitute, but mark evidence and trademark consequences beside the savings. Do not hide development cost inside an optimistic unit number. Record the assumed exchange rate, yield, overfill and defect allowance so purchasing can update the model later. Finally, ask the formulator which base changes each option requires. If one stock forces a new preservative or emulsion, the comparison is no longer a simple ingredient swap. A transparent model prevents marketing from choosing a trade name before operations understands the real commitment.

Questions buyers also ask

Is Matrixyl 3000 the same as Matrixyl Synthe'6?

No. They are distinct commercial peptide systems with different peptide compositions and should not be substituted by trade name.

Which option is cheaper for private label?

It depends on active basis, recommended dose, MOQ, carrier load, testing and packaging. Compare cost per finished unit, not raw-material price alone.

Can both be used in one serum?

Potentially, if the grades are compatible and the formula remains stable, but a combined system adds cost and does not automatically strengthen claims.

Selected source

Use this research as context; it does not replace finished-product substantiation.

• Clinical study of a topical palmitoyl pentapeptide